stockportfolio.pro
ALNY vs IQV: Which Stock Is the Better Buy?
Alnylam Pharmaceuticals, Inc. and IQVIA Holdings Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — ALNY vs IQV, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Alnylam Pharmaceuticals, Inc. (ALNY) | IQVIA Holdings Inc. (IQV) | |
|---|---|---|
| Market cap | $38.9B | $34.6B |
| Revenue (latest FY) | $3.71B | $16.31B |
| Net income (latest FY) | $313.75M | $1.36B |
| Revenue growth (5y CAGR) | 49.8% | 7.5% |
| Net margin | 8.4% | 8.3% |
| Return on equity | 39.8% | 20.9% |
| P/E ratio | 73.0 | 25.7 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 1 | 10 |
| Positive free cash flow | Yes | Yes |
See the full ALNY vs IQV breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open ALNY's full financials → Open IQV's full financials →Frequently asked questions
Which is bigger, ALNY or IQV?
Alnylam Pharmaceuticals, Inc. is larger by market capitalization — $38.9B versus $34.6B.
Which grows faster, ALNY or IQV?
Over the last five fiscal years, Alnylam Pharmaceuticals, Inc. grew revenue faster — 49.8%/yr versus 7.5%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.